Nandrolone Bloodwork: The Complete Monitoring Protocol

Nandrolone is a 19-nor derivative of testosterone, lacking the 19th carbon atom that distinguishes testosterone from other steroids. This structural change has profound effects on its pharmacology, and consequently, on what you need to monitor.

Unlike testosterone, nandrolone has a very low androgenic ratio, approximately 37:37:1 relative to testosterone. This means it binds to the androgen receptor with moderate affinity but produces strong anabolic effects relative to its androgenic activity. The result is excellent muscle growth with relatively low androgenic side effects like hair loss and acne.

When you're monitoring nandrolone, the progestin activity is what sets it apart. It binds to the progesterone receptor, and that binding drives its most recognizable side effects: prolactin elevation, libido suppression, and the infamous "Deca dick." That same progestin activity also feeds into nandrolone's immunosuppressive effects and can drag on your mood.

Nandrolone's ester chain dictates its pharmacokinetics, and the difference between the two common forms is significant. Decanoate, the ester in Deca, carries a half-life of roughly 15 days. That means it takes 75 or more days just to reach steady state in your blood, and you're looking at over 100 days for the compound to fully clear your system. This has a direct and profound impact on your recovery timeline, something we'll break down in detail when we get to the HPTA section.

Prolactin is the single most under-monitored marker in nandrolone users. It is routinely left off standard panels even though nandrolone is one of the most common causes of elevated prolactin among AAS users.

The mechanism is straightforward: nandrolone's progestin activity at the progesterone receptor stimulates prolactin release from the anterior pituitary. This is the same pathway that causes prolactin elevation in pregnancy, where progestin dominance signals the pituitary to increase prolactin production.

When you should act on prolactin really comes down to how you feel. Some guys see their libido tank at levels as low as 20 ng/mL, while others run at 40 ng/mL and don't notice a thing. That said, the research points to 30 ng/mL as the line where intervention is warranted in a male, even if you're not feeling symptoms.

Nandrolone's prolactin elevation differs from the prolactin elevation seen with other causes. Nandrolone-driven prolactin is usually mild to moderate (15-40 ng/mL) compared to the extreme elevations seen with pituitary tumors or antipsychotic medications. However, even mild prolactin elevation has significant effects on sexual function and mood because of nandrolone's concurrent progestin activity. The two mechanisms compound each other at the receptor level.

Nandrolone's impact on lipids is often described as "moderate," which is true compared to orals or trenbolone, but misleading if interpreted as "insignificant." The evidence shows that nandrolone suppresses HDL by approximately 20-35% at typical doses (300-600 mg/week) and raises ApoB and LDL particle number even as total LDL may appear stable.

Nandrolone's lipid impact is real but manageable. The HDL suppression isn't as dramatic as what trenbolone or oral compounds produce, but it's persistent because nandrolone has a long half-life. With testosterone, lipids recover within weeks of stopping. With nandrolone, those lipid effects can stick around for 2-3 months after the last injection.

The 19-nor structure does more than just enable progestin activity. It fundamentally alters how the compound interacts with lipid metabolism enzymes. Understanding this mechanism explains why nandrolone's lipid effects differ from both testosterone and other AAS compounds, and why standard lipid panels can miss the full picture.

Hepatic lipase is the key player here. It's the enzyme that clears HDL particles and remodels LDL, and nandrolone, like all androgens, cranks up its activity. But here's the catch: unlike testosterone, nandrolone's 19-nor structure appears to have a disproportionately strong effect on this enzyme relative to its androgenic potency. So nandrolone can suppress HDL more than you'd expect based on its androgenic rating alone.

The clinical consequence is that nandrolone users often show a shift in HDL subclass distribution, from protective large, buoyant HDL2 particles toward smaller, less protective HDL3 particles, even when total HDL remains within the reference range. This particle shift is invisible on a standard lipid panel and requires advanced testing like NMR lipoprofile or ApoA1 measurement to detect.

19-nor compounds appear to interact with the LDL receptor in a way that sets them apart from other AAS. Nandrolone may upregulate PCSK9, the protein that degrades LDL receptors, which in turn reduces hepatic clearance of LDL particles. That mechanism is well-established for testosterone, but the effect looks stronger with 19-nor compounds. When PCSK9 runs elevated, your liver gets less efficient at pulling LDL out of circulation, and that compounds the atherogenic damage already done by HDL suppression.

Here's the practical side of it. If you're on nandrolone, the standard lipid panel with total cholesterol, HDL, LDL, and triglycerides won't tell you what you need to know. The particle-level changes nandrolone drives are invisible on that panel. You need ApoB, and ideally ApoA1, to see the full picture. When ApoB pushes past 120 mg/dL, or the ApoA1/ApoB ratio drops below 1.0, your cardiovascular risk is elevated, no matter what the standard panel shows.

Clinical research supports this more careful approach to lipid monitoring with 19-nor compounds. A controlled study of nandrolone decanoate (Sattler et al., American Journal of Physiology) found a shift in HDL subfractions — larger, more protective HDL2 particles decreasing while smaller HDL3 particles increased — a pattern that would not necessarily be visible on total HDL alone. This is exactly why total HDL by itself can understate what is happening at the particle level, and why advanced testing (ApoA1, HDL subfractions, or NMR lipoprofile) reveals a shift a standard panel would miss.

Longer-term data on former AAS users (Kanayama et al., Steroids) found that lipid profiles normalized within roughly six months after cessation in most former users, though the study population used a range of compounds, not nandrolone specifically. This suggests the atherogenic effects of 19-nor compounds are not necessarily permanent, but the recovery window is genuinely on the order of months, not days — which is why ongoing ApoB monitoring across a nandrolone cycle and afterward is worth prioritizing rather than assuming a "normal" total cholesterol closes the question.

Nandrolone doesn't just mess with your lipid panel when it comes to cardiovascular health. Hematocrit, blood pressure, and homocysteine are three markers you need to watch closely.

Deca dick" refers to the libido and erectile dysfunction issues tied to nandrolone, and it's one of the most talked-about topics in AAS circles. The usual explanation, that it's just prolactin, doesn't tell the whole story. Deca dick has multiple causes, and you need to understand each one to monitor and manage it properly.

The three contributing factors are:

The practical implication here is straightforward: if you run into Deca dick, don't automatically reach for cabergoline. That's a common reflex, but it's often the wrong move. Checking prolactin and E2 first tells you which mechanism is actually in play, and that information is what makes a conversation with whoever manages your protocol useful rather than a guessing game. If both come back normal yet symptoms persist, you may be one of those athletes who simply does not tolerate nandrolone's progestin activity.

Nandrolone doesn't just mess with your sexual function. It also has significant effects on mood, emotional regulation, and cognitive performance. These effects get far less airtime than Deca dick, but a substantial subset of users report them. If you understand the blood-marker correlations, you can predict and manage these neuropsychiatric effects before they turn into a real problem.

The primary mechanism here is neurosteroid modulation. Nandrolone, like other 19-nor compounds, gets metabolized into neuroactive steroids that interact with GABA-A receptors and serotonin pathways. Testosterone, by contrast, is metabolized into the neurosteroid androstanediol, a positive GABA-A modulator with anxiety-reducing effects. Nandrolone takes a different route: it's metabolized into compounds that may have different, and in some cases opposing, neurosteroid activity.

A clear pattern shows up across nandrolone users who report mood issues, emotional blunting, irritability, or low motivation: it commonly traces back to one of three blood marker profiles.

Emerging evidence now points to nandrolone's effect on serotonin transporter (SERT) activity in the brain. Preclinical models show that 19-nor compounds can alter SERT expression in the hippocampus, which may contribute to mood regulation changes independent of prolactin and E2. This is not yet clinically actionable; you cannot test SERT activity through blood work. But it explains why some athletes experience mood shifts even when all standard markers are optimal.

There's a plausible mechanism behind why the testosterone-to-nandrolone ratio itself seems to matter for mood and libido beyond what prolactin and E2 alone explain: competition at the progesterone receptor, and the role testosterone's own aromatization plays in maintaining adequate E2. That ratio, again, is a protocol decision, not a number to self-apply.

Nandrolone is an injectable compound and does not undergo first-pass liver metabolism, so its direct hepatotoxicity is minimal. But injectable compounds can still affect liver and kidney function through secondary mechanisms, and nandrolone's long half-life means those effects persist longer than with shorter esters.

Nandrolone's effect on kidney function gets blown out of proportion more often than not. The elevated creatinine you see in nandrolone users is mostly driven by increased muscle mass, not by actual kidney damage. That said, the compound is cleared through the kidneys, so if you already have impaired renal function, it can build up in your system. If you've got any history of kidney problems, nandrolone probably isn't the smartest pick for you.

Nandrolone's recovery timeline runs far longer than most athletes expect, and that gap between expectation and reality is exactly where we see the most common mistake in nandrolone users. If you don't plan for it, you're setting yourself up for a rough landing.

Because nandrolone decanoate has a half-life of approximately 15 days, it takes 5-6 half-lives, or 75-90 days, for the compound to clear sufficiently for HPTA recovery to begin. That means even after your cycle ends, you cannot start PCT for another 2-3 months if you want it to be effective.

A 16-week nandrolone cycle can mean 12-18 months of total HPTA suppression on the long end — LH and FSH staying suppressed for over a year after just one cycle is a documented outcome, not a rare edge case.

The reason for this extraordinarily long recovery window lies in nandrolone's effect on the HPTA at multiple levels. At the hypothalamus, it suppresses GnRH pulse frequency through both androgen receptor activation and progestin activity. That progestin component is critical: it adds a secondary suppression mechanism that testosterone alone does not create. Moving to the pituitary, nandrolone directly suppresses LH and FSH synthesis independent of GnRH input. Then at the testicular level, prolonged exposure desensitizes Leydig cells, reducing their capacity to produce testosterone even once LH returns to detectable levels. This triple-level suppression, hypothalamic, pituitary, and testicular, is what makes nandrolone recovery uniquely challenging.

The recovery sequence follows a predictable order. FSH is typically the first marker to show signs of recovery at 4-6 months post-cycle, followed by LH at 6-9 months, and finally endogenous testosterone production at 9-18 months. Spermatogenesis, driven by FSH, often recovers before testosterone production, which means fertility may return months before testosterone reaches acceptable levels. Monitoring FSH specifically, not just LH and total testosterone, gives you the earliest signal that HPTA recovery is beginning. If FSH has not moved from undetectable levels within six months of your last nandrolone injection, full recovery is likely to take 18 months or more.

If you're planning to run nandrolone, get comfortable with the idea of extended HPTA suppression — it is a genuinely demanding recovery profile compared to testosterone alone. Some athletes address this by staying on a testosterone dose between nandrolone cycles rather than fully coming off, but whether that approach makes sense, and at what dose, is a protocol decision for whoever manages it, not a strategy to self-implement from a comparison table.

For a nandrolone cycle, you need a week-by-week monitoring protocol that covers everything specific to this compound. This schedule takes you from prolactin management through the full recovery phase.

If you're planning multiple nandrolone cycles across your lifting career, the cumulative effects deserve serious thought. Each cycle doesn't fully reset to baseline, especially for cardiovascular markers and HPTA function. Understanding those long-term trends is essential for sustainable use.

Data from long-term AAS users shows that cumulative nandrolone exposure tracks with progressively longer recovery times. A first nandrolone cycle might need 6-9 months for full HPTA recovery. By the fifth cycle, even with proper recovery periods in between, that stretches to 12-18 months. The reason isn't that recovery fails between cycles. Each cycle leaves a small residual suppression behind, and those residuals stack up over time. Picture a staircase: every cycle drops you one step down, and every recovery period lifts you one step back up, but you never quite regain the full height of the previous step.

If you're in this for the long haul with nandrolone, get a comprehensive cardiovascular risk assessment (ApoB, Lp(a), homocysteine, hs-CRP) done before your first cycle. That baseline is your reference point for measuring cumulative impact. Retest every 2-3 years, independent of cycle timing, to see whether long-term trends are moving in the right direction. If ApoB runs 10-15 mg/dL higher after five years of intermittent nandrolone use than at baseline, even with full recovery between cycles, the cumulative direction warrants attention and potentially a change in protocol.